Prospective Assessment of Incidence of Fulminant Hepatitis in Post-transfusion Hepatitis: a Study of 504 Cases

Overview

Journal Dig Dis Sci

Specialty Gastroenterology

Date 1994 Jan 1

PMID 7506644

Citations 3

Authors

S Takano

M Omata

M OHTO

Y Satomura

Affiliations

Soon will be listed here.

Abstract

The incidence of posttransfusion hepatitis and "fulminant" hepatitis was investigated by a plan devised at our hospital in December 1982. Of 2959 blood recipients between January 1982 and December 1988, 504 (22.5%) developed posttransfusion hepatitis, with a mean transfusion volume of 10.2 units. Of the 504 cases of posttransfusion hepatitis, "icteric" (T-Bil > 2.0 mg/dl) and "overt icteric" hepatitis (T-Bil > 5.0 mg-dl) developed in 111 cases (22.0%) and 28 cases (5.6%), respectively. Of the 28 overt icteric hepatitis cases, 13 (2.8%) were thought to be true overt icteric posttransfusion hepatitis because the icterus was caused by other reasons in the other 15 cases (seven neonatal jaundice, four hemolytic anemia, one radiation hepatitis, one halothane-induced hepatitis; two other cases were excluded because chronic liver disease was diagnosed by imaging procedures despite serum ALTs in the normal range before transfusion). The anti-HCV serostatus was investigated in five of the 13 true overt icteric posttransfusion hepatitis patients using blood specimens taken 180 days or more following the onset of posttransfusion hepatitis. Anti-HCV seroconversion occurred in three of the five cases (60%). HCV seroconversions were not seen in the cases in which the icterus was due to other reasons.

Citing Articles

Acute hepatitis C virus infection: clinical update and remaining challenges.

Liu C, Kao J Clin Mol Hepatol. 2023; 29(3):623-642.

PMID: 36800699 PMC: 10366792. DOI: 10.3350/cmh.2022.0349.

Chronic Hepatitis C: Acute Exacerbation and Alanine Aminotransferase Flare.

Kanda T, Matsumoto N, Ishii T, Arima S, Shibuya S, Honda M Viruses. 2023; 15(1).

PMID: 36680223 PMC: 9861769. DOI: 10.3390/v15010183.

Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries.

Omata M, Kanda T, Yokosuka O, Crawford D, Al-Mahtab M, Wei L Hepatol Int. 2015; 9(4):486-507.

PMID: 25941137 DOI: 10.1007/s12072-015-9630-4.

References

Kornbluth R, Munis J, Oh P, Meylan P, Richman D . Characterization of a macrophage-tropic HIV strain that does not alter macrophage cytokine production yet protects macrophages from superinfection by vesicular stomatitis virus. AIDS Res Hum Retroviruses. 1990; 6(8):1023-6. DOI: 10.1089/aid.1990.6.1023. View

Watanabe J, Minegishi K, Mitsumori T, Ishifuji M, Oguchi T, Ueda M . Prevalence of anti-HCV antibody in blood donors in the Tokyo area. Vox Sang. 1990; 59(2):86-8. DOI: 10.1111/j.1423-0410.1990.tb05015.x. View

Takano S, Omata M, OHTO M, Satomura Y . Posttransfusion hepatitis in Japan. Vox Sang. 1992; 62(3):156-64. DOI: 10.1111/j.1423-0410.1992.tb01190.x. View

Shimizu M, Ohyama M, Takahashi Y, Udo K, Kojima M, Kametani M . Immunoglobulin M antibody against hepatitis B core antigen for the diagnosis of fulminant type B hepatitis. Gastroenterology. 1983; 84(3):604-10. View

Sheen I, Liaw Y, Chu C, PAO C . Role of hepatitis C virus infection in spontaneous hepatitis B surface antigen clearance during chronic hepatitis B virus infection. J Infect Dis. 1992; 165(5):831-4. DOI: 10.1093/infdis/165.5.831. View

Yanagi M, Kaneko S, Unoura M, Murakami S, Kobayashi K, SUGIHARA J . Hepatitis C virus in fulminant hepatic failure. N Engl J Med. 1991; 324(26):1895-6. DOI: 10.1056/NEJM199106273242615. View

Papaevangelou G, Tassopoulos N, Richardson C . Etiology of fulminant viral hepatitis in Greece. Hepatology. 1984; 4(3):369-72. DOI: 10.1002/hep.1840040304. View

Tateda A, Kikuchi K, NUMAZAKI Y, Shirachi R, Ishida N . Non-B hepatitis in Japanese recipients of blood transfusions: clinical and serologic studies after the introduction of laboratory screening of donor blood for hepatitis B surface antigen. J Infect Dis. 1979; 139(5):511-8. DOI: 10.1093/infdis/139.5.511. View

Yoshiba M, Sekiyama K, Iwamura Y, SUGATA F, Sata M, Kumashiro R . Antibodies to hepatitis C virus in non-A non-B fulminant viral hepatitis. Gastroenterol Jpn. 1990; 25(2):275. DOI: 10.1007/BF02776833. View

10.

Kuo G, Choo Q, Alter H, Gitnick G, Redeker A, Purcell R . An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science. 1989; 244(4902):362-4. DOI: 10.1126/science.2496467. View

11.

Mathiesen L, Skinoj P, Nielsen J, Purcell R, Wong D, Ranek L . Hepatitis type A, B, and non-A non-B in fulminant hepatitis. Gut. 1980; 21(1):72-7. PMC: 1419573. DOI: 10.1136/gut.21.1.72. View

12.

Seeff L, Wright E, ZIMMERMAN H, McCOLLUM R . Va cooperative study of post-transfusion hepatitis, 1969-1974: incidence and characteristics of hepatitis and responsible risk factors. Am J Med Sci. 1975; 270(2):355-62. DOI: 10.1097/00000441-197509000-00018. View

13.

Faisst S, Bartnitzke S, Schlehofer J, zur Hausen H . Persistence of parvovirus H-1 DNA in human B- and T-lymphoma cells. Virus Res. 1990; 16(2):211-23. DOI: 10.1016/0168-1702(90)90024-6. View

14.

Sirchia G, Almini D, Bellobuono A, Giovanetti A, Marconi M, MERCURIALI F . Prevalence of hepatitis C virus antibodies in Italian blood donors. The Italian Cooperative Group. Vox Sang. 1990; 59(1):26-9. DOI: 10.1111/j.1423-0410.1990.tb02109.x. View

15.

AACH R, Stevens C, Hollinger F, Mosley J, Peterson D, Taylor P . Hepatitis C virus infection in post-transfusion hepatitis. An analysis with first- and second-generation assays. N Engl J Med. 1991; 325(19):1325-9. DOI: 10.1056/NEJM199111073251901. View

16.

Kato N, Yokosuka O, Omata M, Hosoda K, OHTO M . Detection of hepatitis C virus ribonucleic acid in the serum by amplification with polymerase chain reaction. J Clin Invest. 1990; 86(5):1764-7. PMC: 296931. DOI: 10.1172/JCI114903. View

17.

Weiner A, Kuo G, Bradley D, Bonino F, Saracco G, Lee C . Detection of hepatitis C viral sequences in non-A, non-B hepatitis. Lancet. 1990; 335(8680):1-3. DOI: 10.1016/0140-6736(90)90134-q. View

18.

Dienstag J . Non-A, non-B hepatitis. I. Recognition, epidemiology, and clinical features. Gastroenterology. 1983; 85(2):439-62. View

19.

Rakela J, Lange S, Ludwig J, Baldus W . Fulminant hepatitis: Mayo Clinic experience with 34 cases. Mayo Clin Proc. 1985; 60(5):289-92. DOI: 10.1016/s0025-6196(12)60534-5. View

20.

Raju G, Broor S, Singh V, Mehta S . Fulminant viral hepatitis: Indian experience. J Gastroenterol Hepatol. 1989; 4(2):161-5. DOI: 10.1111/j.1440-1746.1989.tb00821.x. View